Arcutis Biotherapeutics: FDA Accepts ZORYVE Filing for Infant Eczema
The FDA accepted Arcutis Biotherapeutics' supplemental application to expand ZORYVE cream into infants with atopic dermatitis, with a decision targeted for February 2027.
Label expansions can quietly compound a commercial product's addressable market, and Arcutis Biotherapeutics is chasing exactly that in eczema's youngest patients. On July 8, 2026, the company said the FDA accepted its supplemental New Drug Application for ZORYVE (roflumilast) cream 0.05% in infants aged 3 to 24 months with mild to moderate atopic dermatitis.
Arcutis is a commercial-stage dermatology company built around roflumilast, a once-daily topical phosphodiesterase 4 (PDE4) inhibitor already marketed for several inflammatory skin conditions.
The upside case is incremental but real. ZORYVE cream 0.05% is currently approved for children aged 2 to 5, so a nod for infants down to 3 months would extend a steroid-free option into an earlier, underserved population. The FDA set a PDUFA target action date of February 23, 2027, and the filing is backed by the Phase 3 INTEGUMENT-INFANT trial, which met its primary endpoint with favorable safety and tolerability.
Acceptance of a filing is not approval, and the agency could still decline the expansion. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.
Get the next one first.
Small-cap biotech catalysts, filings and movers — free.